A Long-Term Follow-Up Study of Oral ELND005 (AZD-103) in Subjects With Alzheimer's Disease [Extension of 700022361]

Trial Profile

A Long-Term Follow-Up Study of Oral ELND005 (AZD-103) in Subjects With Alzheimer's Disease [Extension of 700022361]

Completed
Phase of Trial: Phase II

Latest Information Update: 15 May 2015

At a glance

  • Drugs ELND 005 (Primary)
  • Indications Alzheimer's disease
  • Focus Adverse reactions
  • Sponsors Elan Pharmaceuticals
  • Most Recent Events

    • 09 Apr 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top